Crossmark

Combination of Compound Kushen injection with first-line treatment versus first-line treatment alone for advanced colorectal cancer: a study protocol for a multicenter, openlabel, randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s12906-024-04725-6

Published Online: 2024-12-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Jingyuan

Ge, Yuansha

Zhu, Guanghui

Gao, Ruike

Zhu, Xiaoyu

Zhang, Ying

Li, Jie
License Information

Text and Data Mining valid from 2024-12-31

Version of Record valid from 2024-12-31
More Information

Article History

Received: 15 March 2024

Accepted: 6 December 2024

First Online: 31 December 2024

Declarations

:

: Ethical approval for the study has been obtained from the institutional review boards of the Guang'anmen Hospital, China Academy of Chinese Medical Sciences (Number: 2023-063-KY-01, 2023-063-KY-02 and 2023-063-KY-03). An informed consent will be obtained from all subjects and/or their legal guardian(s).

: Not applicable

: The authors declare no competing interests.

Document is current

Any future updates will be listed below